November 21, 2026

To Listing Department, **NATIONAL STOCK EXCHANGE OF INDIA LIMITED** Exchange Plaza, Bandra Kurla Complex, Bandra (E), **MUMBAI -400 051** **Company Code No. AUROPHARMA**	To The Corporate Relations Department **BSE LIMITED** Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street, **MUMBAI -400 001** **Company Code No. 524804**

Dear Sir / Madam,

Sub: Classification of US FDA Inspection at Unit-VI of Apitoria Pharma Private Limited, a wholly owned subsidiary of the Company as VAI– Reg.,

Ref: Our letter dated August 28, 2026

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 this is to inform you that –

The United States Food and Drug Administration (USFDA) inspected Unit-VI, an API manufacturing facility of Apitoria Pharma Private Limited, a wholly owned subsidiary of the Company, situated at E-Bonangi Village, Parawada Mandal, Anakapalli District, 531019, Andhra Pradesh from August 24 to August 28, 2026, and concluded with three observations.

The Unit has now received Establishment Inspection Report (EIR), classifying the facility as "Voluntary Action Indicated" ("VAI"). The USFDA has concluded that this inspection is now closed.

Please take the above information on record.

Yours faithfully,
For AUROBINDO PHARMA LIMITED
Digitally signed by ADI REDDY BADDIGAM
Date: 2026.11.21 09:16:15 +05'30'
B. Adi Reddy
Company Secretary